Symbol="IVA"
AssetType="Common Stock"
Name="Inventiva Sa"
Description="Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidosis (MPS) and other diseases. The company is headquartered in Daix, France."
CIK="1756594"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="50 RUE DE DIJON, DAIX, FR"
FiscalYearEnd="December"
LatestQuarter="2022-12-31"
MarketCapitalization="152619000"
EBITDA="-56314000"
PERatio="None"
PEGRatio="None"
BookValue="1.08"
DividendPerShare="0"
DividendYield="0"
EPS="-1.37"
RevenuePerShareTTM="0.454"
ProfitMargin="-2.885"
OperatingMarginTTM="-3.038"
ReturnOnAssetsTTM="-0.3"
ReturnOnEquityTTM="-0.808"
RevenueTTM="18814000"
GrossProfitTTM="18814000"
DilutedEPSTTM="-1.37"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.428"
AnalystTargetPrice="None"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="19.18"
PriceToBookRatio="2.299"
EVToRevenue="27.43"
EVToEBITDA="-2.04"
Beta="1.021"
num_52WeekHigh="7.47"
num_52WeekLow="2.22"
num_50DayMovingAverage="3.986"
num_200DayMovingAverage="4.212"
SharesOutstanding="41284400"
DividendDate="None"
ExDividendDate="None"
symbol="IVA"
open="3.50"
high="3.58"
low="3.36"
price="3.41"
volume="46881.00"
latest_trading_day="2023-08-25"
previous_close="3.52"
change="-0.11"
change_percent="-3.1250%"
aroon_positive_momentum_days="51"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="51"
Volume_recent_avg="102226"
Change_recent_avg="-0.02"
Delta_recent_avg="0.27"
Variance_recent_avg="0.13"
Change_ratio_recent_avg="-0.67"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="51"
Aroon_momentum_negative="49"
image_negative_thumbnail_id_1="1092"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0125.jpeg"
image_negative_thumbnail_id_2="119"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0057.jpeg"
image_neutral_thumbnail_id_1="560"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0039.jpeg"
image_neutral_thumbnail_id_2="537"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0062.jpeg"
image_positive_thumbnail_id_1="667"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0041.jpeg"
image_positive_thumbnail_id_2="981"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0143.jpeg"
image_professor_thumbnail_id_1="1174"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
image_professor_thumbnail_id_2="1182"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0016.jpeg"
